Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial

Autor: Martin Roumain, Jean-Paul Thissen, Julie Rodriguez, Cándido Robles Sánchez, Julie Anne Nazare, Laure B. Bindels, Miriam Cnop, Stephan C. Bischoff, Jens Walter, Martine Laville, B. Seethaler, Nathalie M. Delzenne, Zhengxiao Zhang, Audrey M. Neyrinck, Patrice D. Cani, Sophie Hiel, Nicolas Paquot, Giulio G. Muccioli
Přispěvatelé: Université Catholique de Louvain = Catholic University of Louvain (UCL), University of Alberta, University of Hohenheim, Walloon Excellence in Life sciences and BIOtechnology [Liège] (WELBIO), Université de Liège, Université libre de Bruxelles (ULB), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University College Cork (UCC), UCL - SSS/LDRI - Louvain Drug Research Institute, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de gastro-entérologie, CarMeN, laboratoire
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Dietary Fiber
0301 basic medicine
medicine.medical_specialty
Microbial metabolites
medicine.medical_treatment
Conjugated linoleic acid
[SDV]Life Sciences [q-bio]
Inulin
Placebo-controlled study
Medicine (miscellaneous)
Prebiotic
030209 endocrinology & metabolism
Gut microbiota
Gut flora
Gastroenterology
Feces
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
fluids and secretions
RNA
Ribosomal
16S
Internal medicine
medicine
Humans
Obesity
Retrospective Studies
Bifidobacterium
Inflammation
2. Zero hunger
030109 nutrition & dietetics
Nutrition and Dietetics
biology
Rumenic acid
business.industry
Original Contribution
Sciences bio-médicales et agricoles
biology.organism_classification
3. Good health
[SDV] Life Sciences [q-bio]
Prebiotics
chemistry
Calprotectin
business
Zdroj: European Journal of Nutrition
European Journal of Nutrition, 2021, Online ahead of print. ⟨10.1007/s00394-021-02484-5⟩
European journal of nutrition, 60 (6
European journal of nutrition, p. [1-12] (2021)
ISSN: 1436-6207
Popis: Purpose Inulin-type fructans (ITF) are prebiotic dietary fibre (DF) that may confer beneficial health effects, by interacting with the gut microbiota. We have tested the hypothesis that a dietary intervention promoting inulin intake versus placebo influences fecal microbial-derived metabolites and markers related to gut integrity and inflammation in obese patients. Methods Microbiota (16S rRNA sequencing), long- and short-chain fatty acids (LCFA, SCFA), bile acids, zonulin, and calprotectin were analyzed in fecal samples obtained from obese patients included in a randomized, placebo-controlled trial. Participants received either 16 g/d native inulin (prebiotic n = 12) versus maltodextrin (placebo n = 12), coupled to dietary advice to consume inulin-rich versus inulin-poor vegetables for 3 months, in addition to dietary caloric restriction. Results Both placebo and prebiotic interventions lowered energy and protein intake. A substantial increase in Bifidobacterium was detected after ITF treatment ( q = 0.049) supporting our recent data obtained in a larger cohort. Interestingly, fecal calprotectin, a marker of gut inflammation, was reduced upon ITF treatment. Both prebiotic and placebo interventions increased the ratio of tauro-conjugated/free bile acids in feces. Prebiotic treatment did not significantly modify fecal SCFA content but it increased fecal rumenic acid, a conjugated linoleic acid ( cis -9, trans -11 CLA) with immunomodulatory properties, that correlated notably to the expansion of Bifidobacterium ( p = 0.031; r = 0.052). Conclusions Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. ClinicalTrials.gov Identifier NCT03852069 (February 22, 2019 retrospectively, registered).
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: